Drugs
-
Health Canada seeks input on new drug review process
Proposed framework would allow Canadian regulator to use drug approval decisions from foreign agencies to speed up approvals in Canada.
-
CMS announces national effort to modernize prior authorization
Shift to all-electronic PA system could save billions, ease provider burden, and create interoperable healthcare ecosystem for the 21st century, says CMS Administrator Oz.
-
Most prior authorization rejections lead to delays or non-approvals
A new study finds that a process designed to ensure patients receive timely and appropriate care may actually be gumming up the works.
-
DOJ, DEA reclassify marijuana products as Schedule III drugs
The changes move products containing marijuana to a less restrictive category, taking significant strides toward the legalization of the drug itself.
-
Rebate debate redux: Revisiting 340B drug pricing
In a high-stakes struggle over the fate of the popular drug pricing program, neither the Trump administration nor safety-net hospital groups seem willing to cede the field.
-
A federal reset for the hemp products market
A Senate agreement to restart federal operations also introduces a stringent framework for hemp-derived cannabinoid products, with significant implications for compliance teams across a $28-billion sector.
-
States fight “most favored” clause in Sandoz deal
Challenge filed in Federal Court by 20 states.